Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Cape Town Merck |
---|---|
Information provided by: | University of Cape Town |
ClinicalTrials.gov Identifier: | NCT00954785 |
The aim of the study is to measure the effectiveness of treatment over 7 days with commonly used anti-inflammatory medications namely etoricoxib and diclofenac (Voltaren) on reducing the severity of pain, swelling and loss of function (range of movement, proprioception) arising from a mild to moderate sprain (partial tear) of the lateral (outer) ligaments of the ankle joint. This injury is commonly known as an ankle sprain.
Condition | Intervention | Phase |
---|---|---|
Sprain |
Device: Ankle brace Drug: Diclofenac 50 mg tds Drug: Etoricoxib 120 mg mane |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Ligaments Sprains: A Clinical Trial |
Estimated Enrollment: | 60 |
Study Start Date: | November 2009 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo drug: Placebo Comparator |
Device: Ankle brace
Sports Stirrup ankle brace (Aircast)
|
Etoricoxib: Experimental |
Device: Ankle brace
Sports Stirrup ankle brace (Aircast)
Drug: Etoricoxib 120 mg mane
In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
|
Diclofenac: Active Comparator |
Device: Ankle brace
Sports Stirrup ankle brace (Aircast)
Drug: Diclofenac 50 mg tds
In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
|
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Grade II ankle sprain injury according to the following: (Rationale: Standard clinical criteria are used to ensure that the severity of injury is similar in all subjects)
This is to ensure that at the time of the first assessment, no subject has taken topical medication, or used ice or compression that may influence the initial assessments of pain and swelling)
Exclusion Criteria:
(Rationale: This is to ensure that subjects only suffer from a soft tissue injury, so that the study group is homogeneous)
Inhibition of prostaglandin synthesis, as caused by these drugs, may cause fluid retention, oedema and hypertension.
Concomitant use of other NSAID's will interfere with outcome measures and these patients have to be excluded from the study)
Contact: Martin P Schwellnus, MBBCh, MD | +27216504562 | martin.schwellnus@uct.ac.za |
Contact: Wayne Derman, MBBCh, PhD | +27216504562 | wayne.derman@uct.ac.za |
South Africa, Western Cape | |
Sports Medicine Clinic, Sports Science Institute of South Africa | |
Cape Town, Western Cape, South Africa, 7700 | |
Kuilsriver Netcare Hospital, 33 Van Riebeeck Road, Kuilsriver | |
Cape Town, Western Cape, South Africa, 7580 |
Principal Investigator: | Martin P Schwellnus, MBBCh, MD | University of Cape Town |
Responsible Party: | University of Cape Town ( Martin Schwellnus, Prof ) |
Study ID Numbers: | IISP 34251, Rec Ref 005/2008 |
Study First Received: | August 6, 2009 |
Last Updated: | August 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00954785 History of Changes |
Health Authority: | South Africa: Medicines Control Council; United States: Food and Drug Administration |
ankle ligament sprain |
non-steroidal anti-inflammatory drugs treatment Acute ankle ligament sprain |
Anti-Inflammatory Agents Analgesics, Non-Narcotic Cyclooxygenase Inhibitors Etoricoxib Wounds and Injuries Diclofenac |
Disorders of Environmental Origin Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Sprains and Strains |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Etoricoxib Physiological Effects of Drugs Wounds and Injuries Disorders of Environmental Origin Diclofenac Enzyme Inhibitors Pharmacologic Actions |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Sprains and Strains |